Innoviva to Participate in Bank of America Merrill Lynch Healthcare Conference on May 17

BRISBANE, Calif.--()--Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, and Eric d'Esparbes, the Company’s Senior Vice President and Chief Financial Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas on Wednesday, May 17 from 4:20 p.m. to 4:50 p.m. PT.

The presentation will be webcast live and a replay will be available one hour after the conclusion of the live event through August 15, 2017 by following this link: Innoviva at BofAML or via the investor relations section of the Innoviva website.

About Innoviva

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc., including the closed triple combination therapy for Chronic Obstructive Pulmonary Disease (COPD). For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

Contacts

Innoviva, Inc.
Eric d'Esparbes, 650-238-9640
Senior Vice President and Chief Financial Officer
investor.relations@inva.com

Recent Stories

RSS feed for Innoviva, Inc.

Innoviva, Inc.